Parabilis Medicines PBLS

Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for historically undruggable protein targets. The company leverages its proprietary Helicon platform to design stabilized helical peptides that can enter cells and bind to flat intracellular protein surfaces, enabling direct modulation of disease-driving proteins previously inaccessible to conventional therapeutics. Its lead product candidate, zolucatetide, targets the β-catenin:TCF interaction in the Wnt/β-catenin signaling pathway, a key driver in multiple cancer types.

Parabilis Medicines, Inc. generates revenue primarily through the advancement and potential commercialization of its proprietary product candidates, including zolucatetide and preclinical programs such as ERG and AR ON degraders. Revenue is derived from collaborations, licensing agreements, and potential future sales of approved therapies, with current financial support coming from equity financings and strategic partnerships. The company serves patients with solid tumors and other diseases driven by genetically validated undruggable targets, focusing on oncology indications with high unmet medical need.

The company operates through the following segments:

• Zolucatetide: This segment focuses on the development and clinical advancement of zolucatetide, the company's lead product candidate designed to inhibit the β-catenin:TCF interaction. Zolucatetide is being evaluated in multiple solid tumor indications including desmoid tumors, familial adenomatous polyposis (FAP), hepatocellular carcinoma (HCC), colorectal cancer (CRC), and additional rare tumors such as adamantinomatous craniopharyngioma (ACP), solid pseudopapillary neoplasm, salivary gland tumors, and ameloblastoma. The segment is supported by clinical data showing tumor reductions in 100% of response-evaluable desmoid tumor patients and a 74% objective response rate in patients with at least two post-baseline scans.
• ERG Degrader: This segment involves the preclinical development of a Helicon-based degrader targeting the ERG protein, an oncogenic driver present in approximately 40-50% of prostate cancer patients via TMPRSS2-ERG fusion. The ERG degrader is designed to induce potent and selective degradation of ERG protein in cells and preclinical models, with observed tumor growth inhibition of 60-95% in cell-line derived xenografts and patient-derived xenograft models. The program is currently advancing toward IND-enabling studies after demonstrating specific degradation of ERG without affecting unrelated proteins.
• AR ON Degrader: This segment encompasses the development of an allosteric AR ON degrader targeting the androgen receptor in its active state to overcome resistance in prostate cancer. The AR ON degrader binds to a distinct co-activator binding site accessible only when androgen is bound to the receptor, enabling combination with existing AR antagonists that target the ligand binding pocket. Preclinical data show robust tumor growth inhibition in AR-amplified models, with the degrader demonstrating activity equivalent to or exceeding approved AR antagonists, and the program is in late lead optimization progressing toward IND-enabling studies.

Parabilis Medicines, Inc. holds a differentiated position in the biopharmaceutical industry through its proprietary Helicon platform, which uniquely combines cell-penetrating ability with high specificity for flat protein surfaces—a capability not consistently achieved by small molecules or biologics. The company faces competition from firms developing gamma-secretase inhibitors for desmoid tumors, such as Merck KGaA’s Ogsiveo and Immunome, Inc.’s varegacestat, as well as other modalities targeting undruggable targets, but believes its Helicon technology provides a durable competitive advantage through its integrated AI-driven discovery engine, proprietary datasets, and ability to generate novel chemical series at scale.

Parabilis Medicines, Inc. serves patients with solid tumors and other diseases driven by Wnt/β-catenin pathway alterations and genetically validated undruggable targets, including individuals with desmoid tumors, familial adenomatous polyposis, hepatocellular carcinoma, colorectal cancer, and rare indications such as adamantinomatous craniopharyngioma, ameloblastoma, and prostate cancer. The company focuses on genetically defined patient populations where its product candidates target root molecular drivers of disease, such as β-catenin or APC mutations, ERG fusions, and androgen receptor activation states.